Our Pipeline

Summary:
4P021 is a CXCR4 antagonist for a curative treatment of acute respiratory distress syndrom (ARDS) and pulmonary complications.

4P021 was developed in collaboration with Prof. Patrick Berger‘s team from CHU de Bordeaux, Bordeaux University and INSERM, SATT Aquitaine, and Prof. François Trottein’s team from Institut Pasteur de Lille.

Today, 4P021 is owned by 4P-Pharma’s SPV – 4Living Biotech.

Epidemiology:
Influenza virus infections are associated to more than 5 million of hospitalization worldwide per year (Lafond et al. 2021).
In France, in 2021, COVID-19 was associated with a minimum of 859 and up to 6,001 (mean 2,669) daily intensive care bed occupancies. In the United States, it was associated with a minimum of 3,525 and a maximum of 28,891 (mean 13,978) daily critical care bed occupancies (Our World in Data website).

Summary:
4P004 is a GLP-1 analog, a potential first-in-class disease modifier drug for osteoarthritis (DMOAD), showing anti-inflammatory, anti-catabolic and anabolic properties.

4P004 was developed in collaboration with the team of Prof. Francis Berenbaum (St-Antoine’s hospital in Paris, APHP and Sorbonne University) and SATT Lutech.

Today, 4P004 is owned by 4P-Pharma’s SPV – 4Moving Biotech.

Milestone:
Phase I trial on OA patients

Market:
≥ 300 Millions of people have OA in the world (Kloppenburg et al., 2020)

Estimated sales per year : 3-4 Milliards/year (GlobalData: https://www.globaldata.com/osteoarthritis-7mm-market-set-to-be-worth-3-5-billion-by-2026/)

Summary:
4P020 is a beta-3 adrenergic receptor agonist developed as a new first-in-class therapeutic drug for Stargardt disease in collaboration with Institut de la Vision and SATT Lutech.

Epidemiology:
Stargardt disease is a rare disease with an estimated prevalence of 1/8,000 – 1/10,000 individuals.(Orphanet)

Summary:

4P020 is a beta-3 adrenergic receptor agonist developed as a new first-in-class therapeutic drug for dry AMD in collaboration with Institut de la Vision and SATT Lutech.

Epidemiology:

With population ageing worldwide, it is estimated that the number of people affected by dry AMD will increase to 230 – 259 Millions in 2040 (Deng et al., 2021)

Summary:
With our partner, Oncocross, a Korea based AI tech company, we are developing an AI platform-based treatment for systemic sclerosis.

Epidemiology:
Systemic sclerosis is a rare disease with an estimated prevalence of 1/6,500 individuals. (Orphanet)

Summary :
In partnerships with Delta 4, an AI tech company based in Vienna (Austria), we join forces to discover and develop a drug candidate from Delta 4’s platform, for the treatment of a rare autoimmune chronic liver disease.